Atlas Trials

Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation

Clinical trial NCT02095782 · TERMINATED

Trial details

NCT number
NCT02095782
Sponsor
Guangdong Association of Clinical Trials
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Non-small-cell Lung Cancer
Start date
2014-03-01
Primary completion
2017-01-20
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.